AVTX Avalo Therapeutics
Price Chart
Executive Summary
Avalo Therapeutics announced positive Phase 2 LOTUS trial results for abdakibart in hidradenitis suppurativa, meeting the primary endpoint HiSCR75 at both doses with response rates of 42.2% (150 mg) and 42.9% (300 mg) vs. 25.6% placebo. The company plans to advance abdakibart into a registrational Phase 3 program, significantly de-risking the asset.
Actionable Insight
Traders should consider initiating long positions given the strong Phase 2 data that supports advancement to Phase 3. Monitor for further details at upcoming medical conferences and enrollment updates for the pivotal program.
Key Facts
- Primary endpoint HiSCR75 met at Week 16: 42.2% (150 mg, p=0.018) and 42.9% (300 mg, p=0.015) vs 25.6% placebo, the highest rates in a trial of this size or larger.
- Statistically significant benefit on key secondary endpoints: HiSCR50, change in IHS4, change in draining tunnel count.
- Abdakibart was well tolerated with no new safety signals; most adverse events mild to moderate.
- Avalo plans to initiate a registrational Phase 3 program based on these results.
Financial Impact
Significant positive catalyst; stock likely to appreciate materially given de-risking of Phase 2 data and clear path to Phase 3. Market cap $368M, potential for upside based on comparable biotech catalysts.
Risk Factors
- Phase 3 trials may fail to replicate efficacy or show unexpected safety issues.
- Competition from existing HS therapies (e.g., adalimumab, secukinumab) and other IL-1β inhibitors.
- Regulatory approval not guaranteed; additional trials may be required.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288197 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
4d ago
|
8-K
| $12.72 awaiting T+5 | awaiting T+5 | — | $14.76 (+16.04%) |
|
May 13, 2026
4w ago
|
8-K
| $19.85 $16.27 | ▼ −18.04% | ▼ −16.88% | $14.76 (−25.64%) |
|
May 13, 2026
4w ago
|
Press Release
| $19.85 $16.27 | ▼ −18.04% | ▼ −16.88% | $14.76 (−25.64%) |
|
May 6, 2026
5w ago
|
Press Release
| $21.81 $19.94 | ▲ +8.57% | ▲ +9.71% | $14.76 (+32.32%) |
|
May 6, 2026
5w ago
|
Insider Cluster
| $21.81 $19.94 | ▲ +8.57% | ▲ +9.71% | $14.76 (+32.32%) |
|
May 5, 2026
5w ago
|
424B5
| $21.81 $19.94 | ▼ −8.57% | ▼ −9.71% | $14.76 (−32.32%) |
|
May 5, 2026
5w ago
|
Press Release
| $21.81 $19.94 | ▼ −8.57% | ▼ −9.71% | $14.76 (−32.32%) |
|
Apr 10, 2026
9w ago
|
DEFA14A
| $13.34 $14.66 | ▲ +9.90% | ▲ +6.60% | $14.76 (+10.64%) |
|
Apr 2, 2026
10w ago
|
Insider Cluster
| $17.76 $13.66 | ▼ −23.09% | ▼ −26.70% | $14.76 (−16.89%) |
|
Apr 1, 2026
10w ago
|
Insider Cluster
| $16.70 $14.21 | ▼ −14.91% | ▼ −18.68% | $14.76 (−11.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access